Exclusive Worldwide License Acquired from Novartis Pharma AG
June 25th 2019
Premark Pharma licenses worldwide rights to PMP2207 for ophthalmic indications and targets a first regulatory approval for blepharitis;
- PMP2207 is a novel ocular formulation of a well-characterised anti-inflammatory medicine, suitable for chronic use
- A 12-week, Phase 2 trial demonstrated a rapid, sustained and clinically meaningful improvement in both the signs and symptoms of blepharitis
- Premark is targeting the first regulatory approval for a prescription treatment for chronic blepharitis – Phase 3 planning is well advanced
- Blepharitis is a chronic inflammatory condition of the eyelids, eyelid margins and ocular surface, affecting more than 10 million people in the United States, with no approved treatment
Basel, June 25, 2019 - Premark Pharma announced today the completion of a licensing deal with Novartis Pharma AG, granting Premark exclusive worldwide rights to develop and commercialise PMP2207, an ophthalmic ointment formulation, as a potential treatment for blepharitis.